Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
D-MNA 200µg · 1 trial · 1 indication
Proportion of subjects with complete histological clearance of the Target Lesion at Visit 5/EV. Histological clearance represents pathological confirmation of treatment response and is interpreted in the context of overall clinical and histological outcomes.
| Arm | Type | Description |
|---|---|---|
| 200µg patch | ACTIVE_COMPARATOR | D-MNA 200µg, intradermal patch, given on day 1, day 8, and day 15. |
| 100µg patch | ACTIVE_COMPARATOR | D-MNA 100µg intradermal patch, given on day 1, day 8, and day 15. |
| Device only (microneedle array alone) arm to assess mechanical and procedural effects. | EXPERIMENTAL | P-MNA, intradermal patch, given on day 1, day 8, and day 15. |
| Name | Type | Description |
|---|---|---|
| D-MNA 200µg | DRUG | D-MNA, (doxorubicin) patch, 200µg |
| D-MNA 100µg | DRUG | D-MNA (doxorubicin) patch, 100µg |
| Microneedle Array Alone | OTHER | P-MNA patch, microneedle array alone |
Key Inclusion Criteria: 1. Male or non-pregnant female ≥ 18 years of age at time of consent. 2. Clinical diagnosis of a primary, previously untreated, histologically confirmed nodular Basal Cell Carcinoma (nBCC) lesion suitable for excision (at end of the study) with a minimum diameter of 0.5 cm an...
D-MNA 200µg is an investigational small molecule being developed for the treatment of nodular basal cell carcinoma, a type of skin cancer. It is administered via microneedle-mediated delivery of doxorubicin. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
D-MNA 200µg delivers doxorubicin, a chemotherapy agent, directly into the tumor through microneedle-mediated delivery. This approach aims to concentrate the drug at the site of the nodular basal cell carcinoma, potentially enhancing its efficacy while minimizing systemic exposure. The specific molecular target is not disclosed.
D-MNA 200µg is being developed by Medicus Pharma Ltd., a biopharmaceutical company. The company is publicly traded under the ticker symbol MDCX. The drug is currently in Phase 2 clinical trials for the treatment of nodular basal cell carcinoma.
D-MNA 200µg is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 2 trial has been completed, and the drug is being evaluated for safety and efficacy in patients with nodular basal cell carcinoma.
D-MNA 200µg has one completed Phase 2 clinical trial, registered under NCT06608238. This randomized, double-blind, active-controlled study enrolled 90 patients with nodular basal cell carcinoma across the United States and United Kingdom. The trial evaluated the safety and efficacy of microneedle-mediated delivery of doxorubicin.
D-MNA 200µg is a formulation that delivers doxorubicin, a well-known chemotherapy drug, through microneedle-mediated delivery. While the active ingredient is doxorubicin, D-MNA 200µg is a specific investigational product developed by Medicus Pharma Ltd. for the treatment of nodular basal cell carcinoma.